BRIEF published on 05/14/2024 at 22:40, 1 year 10 months ago Orlando Credit Union reçoit le prix 2023 de la meilleure coopérative de crédit communautaire pour le nord de la Floride Développement Économique Caisse Populaire D'Orlando Prix 2023 Prêts Aux Petites Entreprises Nord De La Floride
BRIEF published on 05/14/2024 at 22:40, 1 year 10 months ago First 5 Network Challenges California's Proposed State Budget Cuts California Budget Cuts Child Services First 5 Network Medi-Cal Eligibility Early Childhood Education
BRIEF published on 05/14/2024 at 22:40, 1 year 10 months ago Les cinq premiers réseaux remettent en question les réductions budgétaires proposées par l'État de Californie Coupes Budgétaires En Californie Services À L'enfance Premier Réseau 5 Éligibilité Médicale L'éducation De La Petite Enfance
BRIEF published on 05/14/2024 at 22:26, 1 year 10 months ago Bausch Health Announces Updates on Norwich XIFAXAN Litigation and New FDA Submission XIFAXAN Bausch Health Patent Litigation FDA Submission Norwich Pharmaceuticals
BRIEF published on 05/14/2024 at 22:26, 1 year 10 months ago Bausch Health annonce des mises à jour sur le litige Norwich XIFAXAN et une nouvelle soumission à la FDA XIFAXAN Bausch Santé Contentieux Des Brevets Norwich Pharmaceutique Soumission À La FDA
BRIEF published on 05/14/2024 at 22:20, 1 year 10 months ago Sonnet BioTherapeutics Announces Fiscal Year 2024 Q2 Results and Business Updates Financial Results Clinical Trials Oncology Biopharmaceuticals Sonnet BioTherapeutics
BRIEF published on 05/14/2024 at 22:20, 1 year 10 months ago Sonnet BioTherapeutics annonce ses résultats du deuxième trimestre de l'exercice 2024 et des mises à jour sur ses activités Résultats Financiers Essais Cliniques Oncologie Sonnet BioTherapeutics Produits Biopharmaceutiques
BRIEF published on 05/14/2024 at 22:20, 1 year 10 months ago NANOBIOTIX Lance une Étude de Phase 2 sur le Traitement du Cancer du Poumon avec FDA Approval FDA Étude De Phase 2 NANOBIOTIX Cancer Du Poumon NBTXR3
BRIEF published on 05/14/2024 at 22:20, 1 year 10 months ago NANOBIOTIX Launches Phase 2 Lung Cancer Treatment Study with FDA Approval FDA Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer
BRIEF published on 05/14/2024 at 22:15, 1 year 10 months ago GENFIT Announces Q1 2024 Financials and Projects Cash Runway into Late 2025 Cash Position Clinical Trials Revenue Decline Biopharmaceutical Industry GENFIT Financial Results
Published on 03/18/2026 at 12:30, 24 minutes ago Nextech3D.ai Division Achieves Profitability, Signaling Operating Leverage, Margin Expansion and Accelerating Enterprise Momentum
Published on 03/18/2026 at 12:00, 54 minutes ago Irving Resources Receives Assay Results from Its Shika Epithermal Au-Ag Prospect and Announces Its 2026 Exploration Plans for the Noto Peninsula, Honshu, Japan
Published on 03/18/2026 at 12:00, 54 minutes ago Galantas Commences Its First Drill Program at Indiana Gold, Chile
Published on 03/18/2026 at 12:00, 54 minutes ago Nebius Group announces pricing of upsized private offering of $4.0 billion of convertible senior notes
Published on 03/18/2026 at 11:42, 1 hour 12 minutes ago OHB wins EUR 248 million contract for satellite constellation to monitor the Arctic
Published on 03/18/2026 at 10:28, 2 hours 25 minutes ago XTPL sets issue price of series Y shares at PLN 65.00, offering size to reach PLN 19.5 million
Published on 03/18/2026 at 07:00, 5 hours 54 minutes ago Mersen: A resilient performance in 2025, return to growth expected in 2026
Published on 03/18/2026 at 07:00, 5 hours 54 minutes ago Mersen : Performance résiliente en 2025, retour attendu de la croissance en 2026
Published on 03/17/2026 at 23:43, 13 hours 10 minutes ago SUEZ finalise la cession de c. 4% des titres ACEA
Published on 03/17/2026 at 17:45, 19 hours 8 minutes ago SUEZ International SAS lance la cession de titres ACEA
Published on 03/17/2026 at 10:21, 1 day 2 hours ago Communiqué de mise à disposition du Document d'enregistrement universel 2025 incluant le Rapport Financier Annuel
